Resources [1]
Resources designed to support KISQALI prescribers.
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Preview or download resources designed to support KISQALI prescribers. If you would like to get more information or receive copies of any materials, please contact a Novartis representative.
Treatment management
YOUR CHOICE WITH KISQALI
Your Choice is a dedicated support programme designed to facilitate monitoring of KISQALI patients in day-to-day practice.
Find out more [2] Download guide [3]
THERAPY MANAGEMENT GUIDE
This guide provides information for healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.
Download [4]
Patient materials
PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR (AI)
This booklet provides information for patients about what to expect from treatment with KISQALI + AI.
Download [5]
PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT
This booklet provides information for patients about what to expect from treatment with KISQALI + fulvestrant.
Download [6]
Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1
Reference
- KISQALI® (ribociclib) Summary of Product Characteristics.